Lv1
12 积分 2023-12-06 加入
The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications
2天前
已完结
Lipoprotein(a)
18天前
已完结
Novel and future lipid-modulating therapies for the prevention of cardiovascular disease
18天前
已完结
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
1个月前
已完结
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
1个月前
已完结
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
1个月前
已完结
Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment
1个月前
已完结
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
2个月前
已完结
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
2个月前
已完结
CS12192 Reverses Alopecia Areata by Selectively Targeting JAK3/JAK1/TBK1
2个月前
已完结
皖公网安备34019202002308
